DocumentRX-6861
Issued
Read3 min

Trump withdraws Overton, widening FDA leadership gap for sponsors

Heidi Overton’s withdrawal leaves the FDA without a confirmed commissioner, 4,500 staff losses behind, and a priority-voucher pilot stalled, leaving sponsors to plan around uncertain launch timetables.

TAG E-5590 · 580 words on the filing

Overton Withdrawal Extends FDA Leadership Vacuum for Drug Sponsors - PharmTech.com
Overton Withdrawal Extends FDA Leadership Vacuum for Drug Sponsors - PharmTech.comfernandozhiminaicela / pixabay

Summary of findings

  • Overton’s nomination was withdrawn one day before the Senate HELP Committee vote.
  • Three sources cited insufficient congressional support; Republicans held only a one-vote advantage.
  • The FDA has lost more than 4,500 staff over the past year, roughly 20% of its workforce.
  • The National Priority Voucher pilot has issued no vouchers since May 2026.
  • FDA’s mifepristone safety review is due to conclude by March 2027.

President Donald Trump withdrew Heidi Overton’s nomination to lead the FDA one day before a Senate committee vote, extending a leadership vacuum that leaves drug and biologics sponsors facing uncertain review and launch timelines. For sponsors, the immediate issue is whether recent accelerated-review assumptions still hold.

Three people familiar with the matter told Reuters that Overton lacked enough congressional support. Republicans held only a one-vote advantage on the Senate Health, Education, Labor and Pensions Committee, so one defection could have defeated her.

Several HELP members lost their reelection bids: outgoing Chairman Bill Cassidy, a Louisiana Republican and physician; Susan Collins; and Marshall. Cassidy said he “remained undecided.” He had criticized Overton’s involvement in the administration’s efforts to roll back childhood vaccination.

The White House is weighing Sen. Roger Marshall of Kansas as a replacement, two of the sources said. Marshall, a former obstetrician, recently lost his reelection bid. FDA Deputy Commissioner for Food Kyle Diamantas continues to serve as acting commissioner.

Why did Overton’s nomination lose support?

Trump nominated Overton on Aug. 19, 2026. She is a preventive medicine physician and deputy director of the White House Domestic Policy Council. The post had stood vacant since former Commissioner Marty Makary resigned in May.

Confirmation was not guaranteed then, PharmTech reported, and Diamantas had reportedly turned down the commissioner role more than once. Some Trump officials began doubting Overton’s support after Republicans lost control of both chambers in the month’s midterm elections.

Her nomination drew opposition from three policy fronts. Each objection linked her to a live FDA file or administration policy.

  • Vaccines: In August, Overton appeared with Trump at an event promoting an executive order. It called for fewer federally recommended childhood vaccinations and for splitting the measles, mumps and rubella shot into three separate injections. People familiar with the conversations said her support unsettled medical groups and career FDA officials.
  • Mifepristone: Democrats criticized Overton’s stance on the abortion pill. The FDA is conducting a safety review and has said it will conclude by March 2027.
  • Vaping: The nonpartisan advocacy group Health in Office launched a campaign against her nomination. At her September confirmation hearing, she defended FDA’s May authorization of fruit-flavored vapes.

What does the leadership vacuum mean for sponsors?

The FDA has lost more than 4,500 staff over the past year, roughly 20% of its workforce. Since Makary’s departure, the agency has also replaced the acting heads of its drug and biologics review centers.

That turnover is already affecting regulatory planning, Reuters reported. Many of Makary’s acceleration initiatives did not go through formal rulemaking, which leaves them open to reversal.

The National Priority Voucher pilot has issued no vouchers since May. Sponsors that built launch plans and inspection readiness around one- to two-month reviews may now face conventional schedules.

For launch teams, this resembles removing an express lane from a road plan. The submission still must reach its destination, but the journey may take longer.

What happens until a commissioner is confirmed?

A new nominee will face a Senate that Republicans will no longer control. Until confirmation, sponsors face uncertainty over review timelines, guidance priorities, and whether recently introduced programs will survive.

For quality and regulatory teams, submission planning may need to assume established review pathways until the agency’s direction becomes clearer. That is an operating assumption, not proof that the faster model has ended; the available evidence gives no decision date.

via reuters.com (Original)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

10 articles

Linked filings

  1. T-7549
  2. P-6323
  3. E-4696
  4. K-7275
  5. K-3717

Next filing »